Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $283.06 million. The enterprise value is $253.54 million.
Important Dates
The next confirmed earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 99.32 million shares outstanding. The number of shares has increased by 40.22% in one year.
| Current Share Class | 99.32M |
| Shares Outstanding | 99.32M |
| Shares Change (YoY) | +40.22% |
| Shares Change (QoQ) | +4.71% |
| Owned by Insiders (%) | 5.83% |
| Owned by Institutions (%) | 46.31% |
| Float | 93.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.29 |
| Forward PS | 5.28 |
| PB Ratio | -4.65 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.87
| Current Ratio | 4.87 |
| Quick Ratio | 4.32 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.44 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.21% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -49.06% |
| Revenue Per Employee | $381,887 |
| Profits Per Employee | -$381,965 |
| Employee Count | 142 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.30 |
Taxes
| Income Tax | -14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.77% in the last 52 weeks. The beta is 2.02, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 2.02 |
| 52-Week Price Change | -7.77% |
| 50-Day Moving Average | 2.80 |
| 200-Day Moving Average | 3.79 |
| Relative Strength Index (RSI) | 52.73 |
| Average Volume (20 Days) | 986,224 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AQST had revenue of $54.23 million and -$54.24 million in losses. Loss per share was -$0.59.
| Revenue | 54.23M |
| Gross Profit | 37.09M |
| Operating Income | -41.18M |
| Pretax Income | -25.76M |
| Net Income | -54.24M |
| EBITDA | -40.51M |
| EBIT | -41.18M |
| Loss Per Share | -$0.59 |
Full Income StatementBalance Sheet
The company has $68.66 million in cash and $39.14 million in debt, giving a net cash position of $29.52 million or $0.30 per share.
| Cash & Cash Equivalents | 68.66M |
| Total Debt | 39.14M |
| Net Cash | 29.52M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | -60.93M |
| Book Value Per Share | -0.61 |
| Working Capital | 70.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$48.78 million and capital expenditures -$265,000, giving a free cash flow of -$49.04 million.
| Operating Cash Flow | -48.78M |
| Capital Expenditures | -265,000 |
| Free Cash Flow | -49.04M |
| FCF Per Share | -$0.49 |
Full Cash Flow StatementMargins
Gross margin is 68.40%, with operating and profit margins of -75.94% and -100.02%.
| Gross Margin | 68.40% |
| Operating Margin | -75.94% |
| Pretax Margin | -100.05% |
| Profit Margin | -100.02% |
| EBITDA Margin | -74.70% |
| EBIT Margin | -75.94% |
| FCF Margin | n/a |